Although additional studies are needed to address differentiation from vascular and other non‐AD dementias in clinical populations, our findings demonstrate the potential value of considering CVD biomarkers alongside established research criteria such as the National Institute on Aging–Alzheimer's Association Amyloid/Tau/Neurodegeneration Framework.2 The gene discussed is MAPT; the disease is Alzheimer disease.